OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 541 - 550 of 797 studies

Cancer and neoplasms

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy versus Observation after First-line Induction Therapy in Participants with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with Unmutated IGHV (SOUNDTRACK-C1)

Neurological

A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy (Sparkle)

Musculoskeletal

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping (SAFARI44)

Sink-related cleaning practices to prevent transmission of pathogens in healthcare settings

Neurological

CHTT227A12301: A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease (INVEST HD)

A Phase 1/2 Open-label, Dose-escalation, and Dose-expansion Study of mRNA-4194 in Participants with Lynch Syndrome (INTERCEPT-Lynch)

Prospective study of a novel culture-free system for direct pathogen ID and antimicrobial susceptibility testing (RaPIDS)

Cancer and neoplasms

PM54-A-003-25 - A Multcenter Open-label Phase 1/2 Safety Run In and Expansion Study of PM54 in Combination with Immunotherapy (PM54-A-003-25)

Cancer and neoplasms

M25-288 Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Advanced or Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (AndroMETa-PDAC-288)

Cancer and neoplasms

BDTX-4933-101 - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies (BDTX-4933-101)